NCT01787487 2026-03-31
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
11 trialsNCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
NCT04644211 2026-01-08
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Massachusetts General Hospital
Phase 2 Recruiting
NCT03878199 2025-09-15
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT02577926 2025-06-10
Ruxo-BEAT
RWTH Aachen University
Phase 2 Active not recruiting
NCT01375140 2025-06-08
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04116502 2024-11-18
MITHRIDATE
University of Birmingham
Phase 3 Recruiting
NCT05870475 2024-07-03
PV
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT02493530 2024-06-27
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT05566535 2022-10-04
QoL-PV-R
Multinational Center for Quality of Life Research, Russia
Unknown
NCT02267278 2019-06-12
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
M.D. Anderson Cancer Center
Phase 2 Completed